Northwest Biotherapeutics (NWBO) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 3.55.
- Northwest Biotherapeutics' Equity Ratio fell 2990.52% to 3.55 in Q3 2025 from the same period last year, while for Sep 2025 it was 3.55, marking a year-over-year decrease of 2990.52%. This contributed to the annual value of 3.54 for FY2024, which is 4976.73% down from last year.
- As of Q3 2025, Northwest Biotherapeutics' Equity Ratio stood at 3.55, which was down 2990.52% from 3.4 recorded in Q2 2025.
- In the past 5 years, Northwest Biotherapeutics' Equity Ratio registered a high of 1.7 during Q1 2023, and its lowest value of 42.73 during Q3 2023.
- For the 5-year period, Northwest Biotherapeutics' Equity Ratio averaged around 6.46, with its median value being 3.5 (2022).
- Its Equity Ratio has fluctuated over the past 5 years, first plummeted by 112086.1% in 2023, then skyrocketed by 9360.58% in 2024.
- Northwest Biotherapeutics' Equity Ratio (Quarter) stood at 3.09 in 2021, then tumbled by 32.46% to 4.09 in 2022, then soared by 42.28% to 2.36 in 2023, then plummeted by 49.77% to 3.54 in 2024, then decreased by 0.41% to 3.55 in 2025.
- Its Equity Ratio stands at 3.55 for Q3 2025, versus 3.4 for Q2 2025 and 3.62 for Q1 2025.